Drugs / RS001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06894693 | Apr 2025 → Apr 2026 overdue | B-cell non-Hodgkin lymphoma, acute lymphoblastic leukemia | Guangdong Ruishun Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RS001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06894693 ↗ |
| Modality | Cell therapy | “CD19-CAR-mbIL15-DNT Cells.” NCT06894693 ↗ |
| Target | CD19 | “CD19-CAR-mbIL15-DNT Cells.” NCT06894693 ↗ |